Anderlecht

• QIMPD SUBMISSION ONLY Not authorised
  2023-509510-11-00 5 NA
• HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanc … Not authorised
  2024-516253-49-00 4 advanced/metastatic HER2-positive breast carcinoma
• Intubation Conditions in Morbidly Obese Patients with Rapid Sequence Induction: A Comparative Study of Rocuronium Dosing based on Ideal vs. … Not authorised
  2025-520977-37-00 6 Obesity
• Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemo … Pending
  2023-508658-24-00 4 type B3 thymoma and thymic carcinoma
• MInimal residual Disease Adapted Strategy / IFM 2020-02 Pending
  2024-513889-19-00 5 Multiple Myeloma
• Clinical study to check the Efficacy and Safety of Mitapivat in Patients with Sickle Cell Disease Pending
  2024-515202-84-00 10 Anemia in subjects with sickle cell disease (SCD)
• BALLAD Belgium - A trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma. The Belgian component of … Pending
  2024-518349-85-01 5 small bowel adenocarcinoma
• Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Pending
  2024-519655-28-00 5 Premenopausal patients with high-risk HR-positive/HER2-negative breast
• A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cel … Pending
  2024-519786-22-01 9 metastatic non-small cell lung cancer (NSCLC)
• An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH). Pending
  2024-520218-23-00 10 Pulmonary Arterial Hypertension
• RESCAP to prevent peri- and post-surgical complications in open-heart surgery. Pending
  2025-520551-84-00 5 systemic inflammation as side-effect of heart-lung machine during card
• OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending
  2025-520554-11-00 5 Cardiovascular Disease
• A phase 1/2a, first-in-human, open-label, dose-escalating study with a safety expansion cohort to evaluate safety, tolerability, pharmacokin … Pending
  2025-521164-36-00 7 Patients with relapsed/refractory advanced/metastatic ovarian cancer (
• A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu … Pending
  2025-521587-35-00 5 Metastatic colorectal cancer
• Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Pending
  2025-521590-13-00 5 Moderately to Severely Active Crohn’s Disease
• A Study Testing the Investigational Drug XmAb541 in people with Advanced Cancer Pending
  2025-521981-90-00 1 Advanced Solid Tumors
• A Phase 3, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Subjects with Active Pso … Pending
  2025-522586-30-00 5 Psoriatic Arthritis
• Phase 3 Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression Pending
  2025-522748-42-00 5 Ovarian cancer
• A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Pending
  2025-522791-92-00 5 Neoplasm Metastasis
• A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidraden … Pending
  2025-523259-72-00 5 Hidradenitis Suppurativa (HS)
• Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis Pending
  2025-523400-72-00 4 Cystic fibrosis
• PODOMOUNT-Basket, a study to test whether BI 764198 helps adults and adolescents with different types of kidney disease Pending
  2025-523425-17-00 4 Proteinuric kidney diseases
• Phase II study of ezabenlimab in patients with PD-L1-positive head and neck cancer with residual disease detected by ctDNA after chemoradiot … Pending
  2025-523575-36-00 4 Locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
• A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Pending
  2025-523576-23-00 5 Unresectable Stage III non-small cell lung cancer without progression

Showing 1–24 of 445 trials